V
AVXL icon

Veritable’s Anavex Life Sciences AVXL Stock Holding History

Veritable’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-25,000
Closed -$99K – 744
2016
Q4 		$99K Buy
+25,000
New +$89.1K ﹤0.01% 724
2016
Q3 		– Sell
-25,000
Closed -$153K – 729
2016
Q2 		$153K Hold
25,000
– – ﹤0.01% 685
2016
Q1 		$122K Hold
25,000
– – ﹤0.01% 682
2015
Q4 		$139K Buy
+25,000
New +$178K ﹤0.01% 712

Other funds holding AVXL

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Veritable's AVXL Position: Q1 2017 in Review

Veritable sold out of Anavex Life Sciences (AVXL) in Q1 2017, closing a stake of 25,000 shares — an estimated $99K sold.

Veritable first reported a position in AVXL in Q4 2015 and held it in 4 quarters. The position peaked at $153K in Q2 2016. 58 funds tracked by Wall St. Rank hold AVXL as of Q1 2017.

  • Veritable reported no remaining Anavex Life Sciences position as of Q1 2017 after selling out during the quarter.
  • Veritable sold 25,000 Anavex Life Sciences shares in Q1 2017, an estimated $99K.
  • Veritable first reported a position in Anavex Life Sciences in Q4 2015 and held it in 4 quarters.
  • Veritable's Anavex Life Sciences position peaked at $153K in Q2 2016.
  • 58 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2017.

Based on Veritable's 13F filing for Q1 2017, filed 15 May 2017.